Comparative Study Between Antihyperlipidemic Agents in Treatment of Cardiovascular Diseases
NCT ID: NCT07313124
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
66 participants
INTERVENTIONAL
2024-12-15
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Which approach is more effective rosuvastatin monotherapy or rosuvastatin ezetimibe combination antihyperlipidemic for patients with cardiovascular diseases (CVDs)?
* What medical problems do participants could when taking antihyperlipidemic drugs? Researchers will compare rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg to see the effectiveness and safety of these drugs in patients with CVDs.
Participants will:
* Patients will randomize to either rosuvastatin 20 mg or rosuvastatin ezetimibe10/10mg.
* Patients will be followed up to 12 weeks after starting treatment.
* All the patients will be subjected to: Full sheet taking, including detailed history and diagnosis of the case, Baseline Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) tests\& after 24 weeks of treatment, Lipid Profile, creatine kinase (CK) test, Creatine kinase-MB (CK-MB) test.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
NCT07255820
Evaluating Bioequivalence of a Fixed Dose Combination Versus Tablets of Bempedoic Acid / Ezetimibe and Rosuvastatin
NCT07201545
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg
NCT00653445
Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention
NCT06186037
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
NCT00862251
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RosUvastatin
Patients will receive to rosuvastatin 20 mg
rosuvastatin drug
Patients randomized to receive rosuvastatin 20 mg
rosuvastatin ezetimibe10/10mg.
Patients will receive rosuvastatin ezetimibe10/10mg.
Patients received rosuvastatin ezetimibe10/10mg
Patients received rosuvastatin ezetimibe10/10mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rosuvastatin drug
Patients randomized to receive rosuvastatin 20 mg
Patients received rosuvastatin ezetimibe10/10mg
Patients received rosuvastatin ezetimibe10/10mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beni-Suef University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasnaa Osama
Lecturer of Clinical Pharmacy, Beni-Suef University, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beni-Suef University Hospital
Banī Suwayf, Beni Suweif Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kammerer RC, Di Stefano E, Schmitz D. A gas-liquid chromatography assay for phencyclidine and its metabolites. J Anal Toxicol. 1980 Nov-Dec;4(6):293-8. doi: 10.1093/jat/4.6.293.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMBSUREC/05012025/Elsaid
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.